Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Apocard
2. Flcane
3. Flecadura
4. Flecainid Isis
5. Flecainid-isis
6. Flecainide
7. Flecainide Monoacetate
8. Flecainide Monoacetate, (+-)-isomer
9. Flecainide Monoacetate, (r)-isomer
10. Flecainide Monoacetate, (s)-isomer
11. Flecainide, (r)-isomer
12. Flecainide, (s)-isomer
13. Flecainide, 5-ho-n-(6-oxo)-derivative
14. Flecainide, 5-ho-n-(6-oxo)-derivative, (+-)-isomer
15. Flecatab
16. R818
17. Tambocor
1. 54143-56-5
2. Flecainide (acetate)
3. Tambocor
4. R-818
5. Flecainide Monoacetate
6. Flecainide Acetate Salt
7. R 818
8. 54143-56-5 (acetate)
9. N-(2-piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide Acetate
10. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
11. Mls000069675
12. Chebi:5091
13. M8u465q1wq
14. Apocard
15. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, Monoacetate
16. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-,monoacetate
17. N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
18. Smr000058451
19. Acetic Acid;n-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
20. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Acetate
21. Sr-01000000172
22. Einecs 258-997-5
23. Mfcd00214290
24. Unii-m8u465q1wq
25. Flecainidacetat
26. Tambocor (tn)
27. Flecainide Acetate [usan:usp:jan]
28. N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
29. Dsstox_cid_626
30. Opera_id_1587
31. 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidinylmethyl)benzamide Acetate
32. Cas-54143-56-5
33. Dsstox_rid_75700
34. Dsstox_gsid_20626
35. Mls001148177
36. Mls002222300
37. Schembl121583
38. Chembl1200822
39. Dtxsid8020626
40. Flecainide Acetate [jan]
41. Flecainide Acetate (jp17/usp)
42. Flecainide For System Suitability
43. Flecainide Acetate [usan]
44. Flecainide Acetate [vandf]
45. Hms1570c12
46. Hms2097c12
47. Hms2231e15
48. Hms3259f11
49. Hms3267n04
50. Hms3369m07
51. Hms3412d09
52. Hms3676d09
53. Hms3714c12
54. Flecainide Acetate [mart.]
55. 11a-hydroxyepoxyprogesterone
56. Bcp17825
57. Flecainide Acetate [usp-rs]
58. Flecainide Acetate [who-dd]
59. Tox21_200208
60. Akos015889993
61. N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide Acetate
62. Ccg-220735
63. Cs-1400
64. Nc00641
65. Sb19142
66. Flecainide Acetate [ep Impurity]
67. Flecainide Acetate [orange Book]
68. Flecainide Acetate [ep Monograph]
69. Flecainide Acetate [usp Impurity]
70. Ncgc00093934-01
71. Ncgc00093934-02
72. Ncgc00257762-01
73. As-11702
74. Flecainide Acetate [usp Monograph]
75. Hy-17429
76. Db-052497
77. Eu-0100546
78. Ft-0630667
79. En300-51344
80. D00638
81. E-0735
82. F 6777
83. 143f565
84. Sr-01000000172-2
85. Sr-01000000172-4
86. Sr-01000000172-5
87. Sr-01000000172-7
88. Q27089351
89. Flecainide Acetate, British Pharmacopoeia (bp) Reference Standard
90. Flecainide Acetate, European Pharmacopoeia (ep) Reference Standard
91. 2,5-bis(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)benzamide Acetate
92. Flecainide Acetate, United States Pharmacopeia (usp) Reference Standard
93. 2-({[2,5-bis(2,2,2-trifluoroethoxy)benzoyl]amino}methyl)piperidinium Acetate
94. Flecainide For System Suitability, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 474.4 g/mol |
---|---|
Molecular Formula | C19H24F6N2O5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 474.15894084 g/mol |
Monoisotopic Mass | 474.15894084 g/mol |
Topological Polar Surface Area | 96.9 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 531 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Flecainide acetate |
Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
Active Ingredient | Flecainide acetate |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 50mg; 150mg |
Market Status | Prescription |
Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
2 of 2 | |
---|---|
Drug Name | Flecainide acetate |
Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
Active Ingredient | Flecainide acetate |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 50mg; 150mg |
Market Status | Prescription |
Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15244
Submission : 2001-01-15
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-26
Pay. Date : 2023-08-29
DMF Number : 35760
Submission : 2021-03-31
Status : Active
Type : II
Certificate Number : CEP 2021-393 - Rev 00
Issue Date : 2024-06-10
Type : Chemical
Substance Number : 1324
Status : Valid
NDC Package Code : 72640-021
Start Marketing Date : 2021-03-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-09-06
Pay. Date : 2022-07-01
DMF Number : 37212
Submission : 2022-06-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33666
Submission : 2019-03-29
Status : Active
Type : II
Certificate Number : CEP 2020-054 - Rev 02
Issue Date : 2024-05-30
Type : Chemical
Substance Number : 1324
Status : Valid
Date of Issue : 2021-08-06
Valid Till : 2024-03-04
Written Confirmation Number : WC-0294
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19272
Submission : 2006-03-23
Status : Active
Type : II
Certificate Number : R1-CEP 2009-289 - Rev 01
Issue Date : 2015-03-19
Type : Chemical
Substance Number : 1324
Status : Suspended by Holder
Date of Issue : 2024-04-23
Valid Till : 2027-04-22
Written Confirmation Number : WC-0170
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-07
Pay. Date : 2014-02-01
DMF Number : 23192
Submission : 2009-10-14
Status : Active
Type : II
Certificate Number : R1-CEP 2006-005 - Rev 02
Issue Date : 2020-08-13
Type : Chemical
Substance Number : 1324
Status : Suspended by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14749
Submission : 2000-02-29
Status : Active
Type : II
Certificate Number : CEP 2009-363 - Rev 03
Issue Date : 2023-12-06
Type : Chemical
Substance Number : 1324
Status : Valid
Registration Number : 223MF10093
Registrant's Address : VIALE DEL GHISALLO, 20 20151 MILAN ITALY
Initial Date of Registration : 2011-06-29
Latest Date of Registration : --
NDC Package Code : 17373-1283
Start Marketing Date : 2009-07-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?